Modality
Multispecific
MOA
PD-1i
Target
IL-23
Pathway
Cell Cycle
PsAADHD
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
Dec 2018
→ Nov 2028
Phase 2Current
NCT03578453
1,372 pts·PsA
2021-01→TBD·Recruiting
NCT05088809
1,518 pts·PsA
2018-12→2028-11·Terminated
2,890 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-202.6y awayPh2 Data· PsA
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2028-11-20 · 2.6y away
PsA
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03578453 | Phase 2 | PsA | Recruiting | 1372 | MRD |
| NCT05088809 | Phase 2 | PsA | Terminated | 1518 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Gelisertib | Samsung Biologics | Approved | IL-23 | |
| Talafotisoran | Blueprint Medicines | Phase 2/3 | IL-23 |